WALTHAM, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX) ("TScan" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of T cell ...
While it works on certain targets with Novartis, TScan is developing its own pipeline, which includes programs in blood cancers and solid tumors. (TScan Therapeutics) (TScan Therapeutics ) Last summer ...
From what we can see, insiders were net buyers in TScan Therapeutics, Inc.'s (NASDAQ:TCRX ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While ...
Executive Summary TScan’s presentation focused on two main programs: its hematologic malignancies (HEME) program, which has shown promising Phase 1 data, and its solid tumor program utilizing a ...
Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary ...
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The following table summarizes their recent ratings, shedding ...
Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to ...
TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) engineered T cell therapies, stands at a critical juncture in its development pipeline. With key ...
Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results